| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.RES.29.6.673 |
| P698 | PubMed publication ID | 4331483 |
| P2093 | author name string | Pals DT | |
| Fessler DC | |||
| Masucci FD | |||
| Denning GS Jr | |||
| Sipos F | |||
| P433 | issue | 6 | |
| P304 | page(s) | 673-681 | |
| P577 | publication date | 1971-12-01 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Role of the pressor action of angiotensin II in experimental hypertension. | |
| P478 | volume | 29 |
| Q40216621 | (7-Ile) angiotensin III: A relatively selective antagonist of angiotensin steroidogenesis |
| Q40087229 | 8 Renin in essential hypertension |
| Q68692725 | A comparative study of two structurally related analogs of Asp1-Ile5-angiotensin II |
| Q36097049 | A comparison of the ability of two angiotensin II receptor blocking drugs, 1-Sar; 8-Ala angiotensin II and 1-Sar, 8-Ile angiotensin II, to modify the regulation of glomerular filtration rate in the cat. |
| Q67263989 | A substrate analog inhibitor of renin that is effective in vivo |
| Q35537965 | Acute and long-term studies of the mechanisms of action of beta-blocking drugs in lowering blood pressure |
| Q39139190 | Additive Effect of Beta-Adrenergic Blockers in Combination with Vasodilators in Lowering Blood Pressure |
| Q40317304 | Altered renin release and propranolol potentiation of vasodilatory drug hypotension |
| Q40818046 | Angiotensin Blockade in Renovascular Hypertension: A Controlled, Prospective Study |
| Q72928246 | Angiotensin II is a necessary component for the development of hypertension in the two kidney, one clip rat |
| Q43634235 | Angiotensin II: Intratubular and Renal Capillary Pressure Regulation in the Rat Kidney |
| Q70003048 | Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure |
| Q37151964 | Are we poised to target ACE2 for the next generation of antihypertensives? |
| Q35196088 | Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man |
| Q54624835 | Blockade of the systemic and renal vascular actions of angiotensin II with the 1-SAR, 8-ALA analogue in the rat |
| Q45030423 | Blockage of Ovulation by an Angiotensin Antagonist |
| Q70253240 | Cardiovascular responses of conscious DOCA-salt hypertensive rats to acute intracerebroventricular and intravenous administration of captopril |
| Q28566624 | Changes in the subcellular distribution of NADPH oxidase subunit p47phox in dendrites of rat dorsomedial nucleus tractus solitarius neurons in response to chronic administration of hypertensive agents |
| Q40183353 | Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats |
| Q51856083 | Circulatory Effects of Renin-Angiotensin System Antagonists during Halothane Anaesthesia in Hypertensive Rats |
| Q41763745 | Clinical value of plasma renin determinations in renovascular and primary hypertension |
| Q40300834 | Concepts in hypertension. The Croonian Lecture 1979. |
| Q36004312 | Conversion of angiotensin I to angiotensin II in the human foetoplacental vascular bed |
| Q37113027 | Converting enzyme inhibition and blood pressure regulation |
| Q37717051 | Converting enzyme, angiotensin II and hypertensive disease |
| Q39472653 | Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors |
| Q44609310 | Critical analysis of the saralasintest in the diagnosis of hypertension (author's transl) |
| Q37013698 | Decreased adrenal responsiveness to angiotensin II: a defect present in spontaneously hypertensive rats. A possible model of human essential hypertension |
| Q41434041 | Differences in mortality rate between abrupt and progressive carotid ligation in the gerbil: role of endogenous angiotensin II. |
| Q66942266 | Editorial: New prospects in renal hypertension |
| Q44998486 | Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis |
| Q53778067 | Effects of chronic administration of prostaglandin E1 (PGE1) on arterial blood pressure of unanesthetized hypertensive rats |
| Q28323054 | Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats |
| Q77982391 | Effects of peptide and non-peptide antagonists of angiotensin II receptors on drinking behavior in rats |
| Q72113785 | Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models |
| Q50797661 | Endogenous angiotensin II receptors in Xenopus oocytes and eggs |
| Q40024598 | Estimating renin participation in hypertension: Superiority of converting enzyme inhibitor over saralasin |
| Q48381506 | Evidence for sar1-ala8-angiotensin crossing the blood cerebrospinal fluid barrier to antagonize central effects of angiotensin II |
| Q54527077 | Experimental renal hypertension in pregnant sheep. II. Response to a one-kidney model. |
| Q40000291 | Formation of angiotensin III by angiotensin-converting enzyme |
| Q68711389 | Hormone-receptor interations. Synthesis of a biologically active cysteinyl-angiotensin derivative and its use for the preparation of spin-labelled and polymer-supported molecules |
| Q72621799 | Humoral and neurogenic factors in two-kidney renovascular hypertension |
| Q28581285 | Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory |
| Q71941300 | In vitro pharmacological characterization of UP 269‐6, a novel nonpeptide angiotensin II receptor antagonist |
| Q40316577 | Influence of the adrenal gland on the pressor effect and antagonistic potency of angiotensin II analogs |
| Q70029137 | Infusion of angiotensin-II analogue in two patients with unilateral renovascular hypertension |
| Q34516435 | Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor |
| Q38044163 | Interrelations between various blood pressure regulatory systems and the mosaic theory of hypertension |
| Q39720635 | Interrelationship Between Renal Haemodynamics, Drug Kinetics and Drug Action |
| Q70007159 | Letter: Angiotensin blockade |
| Q36077711 | Morphometric analysis of hypertension-induced hypertrophy of rat thoracic aorta |
| Q31160630 | N-Aryl Isoleucine Derivatives as Angiotensin II AT2 Receptor Ligands |
| Q67379416 | Negative saralasin response in correctable renovascular hypertension |
| Q37599394 | Not just angiotensinases: new roles for the angiotensin-converting enzymes |
| Q28378315 | Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277 |
| Q28378367 | Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype |
| Q40024453 | Rat brain iso-renin [proceedings] |
| Q66950584 | Reciprocation of Renin Dependency with Sodium Volume Dependency in Renal Hypertension |
| Q68653009 | Relationship between the renin-angiotensin system and the autonomic nervous system |
| Q67015661 | Renal responses to angiotensin II and 1-sar-8-ala-AII in sodium replete and deplete dogs |
| Q40318447 | Renin Release, Saralasin and the Vasodilator-Beta-Blocker Drug Interaction in Man |
| Q39377616 | Renin dependency of blood-pressure. Analysis by angiotensin II antagonist P113 in hypertensive patients treated with salt depletion and propranolol |
| Q67793382 | Renin, aldosterone and arterial pressure responses to acute beta-adrenergic receptor blockage in hypertensive patients |
| Q72608530 | Renin-like effects of NGF evaluated using renin-angiotensin antagonists |
| Q67299997 | Renovascular hypertension |
| Q36998761 | Renovascular hypertension: pathophysiology, diagnosis, and treatment |
| Q74824312 | Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis |
| Q36273600 | Role of extrapulmonary conversion in mediating the systemic pressor activity of angiotensin I. |
| Q67746658 | Role of the Renin-Angiotensin System in Renal Hypertension. An Experimental Approach |
| Q36013124 | Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy |
| Q41440410 | Sar1Ile7angiotensin III, a new selective antagonist of the pressor effect of angiotensin III in conscious rats |
| Q35329815 | Saralasin and Sarile Are AT2 Receptor Agonists |
| Q54526156 | Studies on the Mechanism of the Enhancement of the Antihypertensive Activity of Captopril by A Diuretic in Spontaneously Hypertensive Rats |
| Q67319791 | Study of sar1-ala8 angiotension II (Saralasin) responsiveness in hypertension of renal origin7 |
| Q40121435 | The Biochemistry of the Renin-Angiotensin System |
| Q53743203 | The adrenal cortex and the kidney. |
| Q73302764 | The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling |
| Q28321084 | The biochemistry of the renin-angiotensin system and its role in hypertension |
| Q67837823 | The effect of saralasin (1sar-8-ala-angiotensin II) on blood pressure in patients with Cushing's syndrome |
| Q40076981 | The pharmacology of drinking behavior |
| Q34518146 | The pressor actions of noradrenaline, angiotensin II and saralasin in chronic autonomic failure treated with fludrocortisone |
| Q38038818 | The renin-angiotensin system and hypertension |
| Q54638663 | The role of angiotensin in the cardiovascular and renal response to salt restriction. |
| Q39857460 | The role of renin in the control of the circulation and in hypertensive disease |
| Q40310065 | Use of an Angiotensin II Antagonist (Saralasin) in the Recognition of “Angiotensinogenic” Hypertension |
| Q67430532 | Vasoactive peptides in experimental renal hypertension |
| Q68645511 | [Kidney and hypertension] |
Search more.